MASCC Oncodermatology Study Group
Leadership
Chair: Jennifer Choi, MD - USA
Vice-Chair: Mario E Lacouture, MD - USA
For more information or to contact the Study Group Leaders, please send an email to [email protected].
Mission
The mission of the MASCC Oncodermatology Study Group is to develop research and management strategies for skin conditions due to cancer or anticancer drugs. Skin reactions are frequent in those affected by cancer. They can reduce quality of life and require modifications in lifesaving antineoplastic therapy. This interdisciplinary Study Group aims to raise awareness of dermatological conditions in cancer patients and take a leadership role in the emerging field of cancer-related skin toxicities management.
Objectives
The objectives of the Oncodermatology Study Group include the following:
- To identify new targets for the treatment of skin reactions
- To establish guidelines for management
- To contribute to patients' knowledge of reactions and their care.
Key efforts are directed toward the identification of phenotypes and treatment regimens with a higher risk, as well as preventive measures and early intervention as standards of care. This Study Group also serves as a resource for multicenter clinical trials and translational studies.
 Guidelines & Assessment Tools
Practice Guidelines
The Oncodermatology Study Group undertook a project to determine treatment recommendations for the management of skin problems caused by EGFRI agents. Members of the Study Group volunteered to review and evaluate research and articles in each of eight categories of skin toxicity. A selected group of eight experts agreed to serve as a recommendations panel. This group met to determine treatment recommendations on the basis of research findings and expert opinion. This effort resulted in a set of clinical practice guidelines, published in Supportive Care in Cancer.
Lacouture ME, Anadkat MJ, Bensadoun RJ, Bryce J, Chan A, Epstein JB, et al; for MASCC Skin Toxicity Study Group. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer. 2011 Aug;19(8):1079-95.
MASCC appreciates the unrestricted grants from BMS, EvoLife, OSI, and Amgen.
Subsequently, a CME-certified slide set was developed, in which Dr. Lacouture provides a case-based review of the MASCC guidelines for preventing and treating dermatologic toxicities in patients receiving EGFR inhibitors:
EGFR Inhibitor–Related Dermatologic Toxicities: Applying MASCC Guidelines in Prevention and Treatment
Upon completion of this activity, participants should be able to do the following:
- Administer effective prophylactic treatment strategies for dermatologic toxicities associated with EGFR inhibitors in oncology patients receiving therapy with these agents
- Employ optimal management strategies for long-term treatment-related adverse events associated with EGFR inhibitors
- Identify and treat dermatologic infections associated with EGFR inhibitor therapy in oncology patients receiving treatment with these agents
- Counsel patients on the anticipated dermatologic toxicities associated with EGFR inhibitors and optimal prophylactic and management strategies
MASCC EGFR Inhibitor Skin Toxicity Tool© (MESTT) (1.1MB ppt)
Developed by the MASCC Skin Toxicity Study Group in 2008.
Caring for your skin, hair and nails on "Targeted Therapies"  - Download this brochure for patients with EGFRI side effects.
Clinical Guidelines
Clinical practice guidelines for the prevention and treatment of acute and late radiation reactions from the MASCC Skin Toxicity Study Group. Wong RK, Bensadoun RJ, Boers-Doets CB, Bryce J, Chan A, Epstein JB, Eaby-Sandy B, Lacouture ME. Support Care Cancer. 2013 Oct;21(10):2933-48.
Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Lacouture ME, Anadkat MJ, Bensadoun RJ, Bryce J, Chan A, Epstein JB, Eaby-Sandy B, Murphy BA; MASCC Skin Toxicity Study Group. Support Care Cancer. 2011 Aug;19(8):1079-95. Free Full Text
Research Highlight
Predicting Diarrhea and Rash in Breast Cancer Patients Treated with Lapatinib and Capecitabine
Study Group Co-Chair Mario Lacouture has collaborated with Dr. George Dranitsaris of Augmentium Pharma Consulting in Toronto, Ontario, on the development of models for predicting patient-specific risks of diarrhea and rash in breast cancer patients being treated with lapatnib and capecitabine. The work was published in Breast Cancer Res Treat. in October, 2014. >> Read more
Past Workshops
Recent Member Publications
Recent Study Group member publications related to Oncodermatology in cancer patients.
Books
Dermatologic Principles and Practice in Oncology: Conditions of the Skin, Hair, and Nails in Cancer Patients - Mario E. Lacouture. 2014
This is the first book to focus on frequent and frequently disabling side effects involving the skin, hair, and nails in cancer patients. It provides detailed descriptions of mechanism-of-action in all current oncology drugs and the clinical presentation and mechanisms underlying their dermatologic side effects, alongside carefully presented treatment recommendations, allowing physicians to significantly enhance their care of patients with cancer.
Dr. Lacouture's Skin Care Guide for People Living With Cancer - Written by MASCC Member, Dr. Mario Lacouture, an expert in the dermatologic side effects of anti-cancer medications. this book offers clear information and practical suggestions for preventing, treating, and living through these skin, hair, and nail changes.
Please contact the Study Group Chairs above with your questions.
MASCC Study Group Coordinator, Leslie Johnson
|
